ClinicalTrials.gg
CompletedNCT04998851SOPRANINOUpdated Jan 14, 2026Results posted

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

A Phase 4 interventional study of Ocrelizumab in Multiple Sclerosis and Clinically Isolated Syndrome, sponsored by Hoffmann-La Roche. Completed at 8 sites in 3 countries. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
23rd of 27
26 · median 170
Started
2021
with 1 other
Phase 4
11 of 27
1 open now
Registered
17th of 27
by date
Lead sponsor
13 of 27
Hoffmann-La Roche

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 23rd largest by enrollment, is one of 2 that started in 2021, is one of 11 in phase 4, and was the 17th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) in the infants.

03

Conditions studied

  • Multiple Sclerosis
  • Clinically Isolated Syndrome

Keywords

  • ocrelizumab, OCREVUS, breastmilk transfer, breast milk transfer, lactation
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Woman is between 18 and 40 years of age at screening
  • Woman is willing to breastfeed for at least 60 days after the first post-partum ocrelizumab infusion (this decision is to be taken prior to and independent from study participation)
  • Woman is willing to provide breastmilk samples
  • Woman has a diagnosis of MS or CIS (in line with the locally approved indications)
  • Woman has delivered a healthy term singleton infant (≥37 weeks gestation)
  • Infant is between 2-24 weeks of age at the time of the mother's first post-partum dose of ocrelizumab
  • For women who received commercial ocrelizumab (OCREVUS) before enrolment: documentation that last exposure to ocrelizumab occurred more than 3 months before the last menstrual period (LMP) and was given at the approved dose of 2 x 300 mg or 1 x 600 mg
  • Woman agrees to use acceptable methods during the study

Exclusion Criteria related to the Mother:

  • to ocrelizumab or to any of its
  • Received last dose of ocrelizumab \<3 months before the LMP or during pregnancy
  • Active infections (may be included once the infection is treated and is resolved; women with bilateral mastitis infection should not have samples collected until the infection is completely resolved)
  • Prior or current history of primary or secondary immunodeficiency, or woman in an otherwise severely state
  • Known active , or being actively monitored for recurrence of malignancy
  • History of breast implants, breast augmentation, breast reduction surgery or mastectomy
  • Prior or current history of chronic alcohol abuse or drug abuse
  • Positive screening tests for
  • Treatment with a DMT for CIS or MS during pregnancy and/or first weeks post-partum, with the exception of formulations of interferon-beta, glatiramer acetate or pulsed
  • Treatment with drugs known to transfer to the breastmilk and with established or potential deleterious effects for the infant
  • Treatment with any agent within 6 months or five half-lives of the investigational drug prior to the LMP

Exclusion Criteria related to the Infant:

  • >24 weeks of life at the time of the mother's first dose of ocrelizumab
  • Any abnormality that may interfere with breastfeeding or milk absorption
  • Active infection (may be included once the infection resolves)
  • Infant has any other medical condition or abnormality that, in the opinion of the investigator, could compromise the infant's ability to participate in this study, including interference with the interpretation of study results
  • At least one documented brief resolved unexplained event (BRUE), as defined by the 2016 Guidelines of the American Academy of Pediatrics
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Women with CIS or MS

    Lactating women with CIS or MS (in line with the locally approved indications) who decided together with their treating physician to continue on, or start treatment with, OCREVUS (ocrelizumab) post-partum. Women resuming treatment with ocrelizumab post-partum will be included only if the last exposure to ocrelizumab occurred more than 3 months before the last menstrual period to exclude any interference between fetal exposure and exposure via lactation.

    Drug: Ocrelizumab

Interventions

  • Women will receive the ocrelizumab dose regimen as per the locally-approved label. The ocrelizumab dose will be administered as an initial split dose of two 300 mg infusions separated by 14 days or a single 600 mg infusion according to the local prescribing information.

06

What researchers measure

Primary outcomes

  1. Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First Ocrelizumab Postpartum Infusion

    Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose). The percentage of infants with B cell levels below LLN are reported with the two-sided Clopper Pearson 95% confidence interval (CI). B-cell reference ranges by week of life (absolute and percentage counts) are defined by Borriello et al. 2022.

    Time frame: At Day 30

  2. Estimated Average Oral Daily Infant Dosage (ADID)

    ADID was calculated as the arithmetic mean of the mother's daily ocrelizumab milk concentration (micrograms/milliliters \[µg/mL\]) over 60 days post-ocrelizumab infusion 1 multiplied by an estimated infant milk intake of 150 milliliters/kilograms/day (mL/kg/day) and based on the weight \[kilograms (kg)\] recorded at the Day 30 visit. Ocrelizumab concentrations reported as below the lower limit of quantification \[LLQ=160 nanograms/millilitres (ng/mL)\] are imputed to zero for the calculation ADID.

    Time frame: Up to Day 60

Secondary outcomes

  1. Absolute CD19+ B Cell Count in the Infant

    Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose).

    Time frame: At Day 30

  2. Percentage of CD19+ B Cell in the Infant

    Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose).

    Time frame: At Day 30

  3. Area Under the Milk Concentration-Time Curve (AUC) of Ocrelizumab in Mature Breastmilk

    Time frame: One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1

  4. Average Concentration of Ocrelizumab in Breastmilk (Cmean)

    Time frame: One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1

  5. Maximum Concentration (Cmax) of Ocrelizumab in Breastmilk

    Time frame: One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1

  6. Time of Maximum Concentration (Tmax) of Ocrelizumab in Breastmilk

    Time frame: One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1

  7. Estimated Maximum Oral Daily Infant Dosage (MDID)

    MDID was calculated at the subject level as the peak ocrelizumab milk concentration (μg/mL) multiplied by an estimated infant milk intake of 150 mL/kg/day measured over 60 days after the mother's first postpartum ocrelizumab infusion.

    Time frame: Up to Day 60

  8. Average Relative Infant Dose (RID)

    Average RID over 60 days was calculated as the ADID (mg/kg/day) divided by the maternal dosage (mg/kg/day) over 60 days multiplied by 100.

    Time frame: Up to Day 60

  9. Serum Concentration of Ocrelizumab in the Infant at Day 30

    Serum concentration of ocrelizumab in the infant measured at Day 30 after the mother's first ocrelizumab postpartum infusion. Concentrations reported as below the lower limit of quantification (LLQ=156 ng/mL) are set to zero for calculation of summary statistics.

    Time frame: At Day 30

  10. Percentage of Mothers With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

    Time frame: Up to approximately 73.3 weeks after first ocrelizumab dose

  11. Percentage of Infants With AEs

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

    Time frame: Up to approximately 73.3 weeks after first ocrelizumab dose administered to mother

  12. Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to Measles, Mumps, and Rubella (MMR) Vaccination

    The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. mIU/mL=milli-international units per milliliter.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  13. Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination

    The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. RU/mL=relative units per milliliter.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  14. Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination

    The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. IU/mL=international units per milliliter.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  15. Percentage of Infants With Positive Humoral Response to MMR Vaccination

    Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for MMR vaccine are as follows: Anti-Measles Vir IgG(-70)CL: ≥ 120 mIU/mL; Anti-MumpsAT Vir iGG(-70)CL: ≥ 17 RU/mL; Anti-Rub Vir IgG(-70)RUOCL: ≥ 10 IU/mL.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  16. Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccine

    The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  17. Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccine

    The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative * COI 0.95-1.04: Equivocal * COI \> 1.04: Positive The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  18. Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccine

    The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  19. Percentage of Infants With Positive Humoral Response to DTP Vaccine

    The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative * COI 0.95-1.04: Equivocal * COI \> 1.04: Positive The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  20. Mean Titers of Haemophilus Influenzae Type B (Hib), IgG Antibody in Response to Hib Vaccine

    The immune response to Hib vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  21. Percentage of Infants With Positive Humoral Response to Hib Vaccine

    Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for Hib vaccine are as follows: Hib, IgG: ≥ 0.15 µg/mL.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  22. Mean Titers of Anti-Hepatitis B Surface Antibody in Response to Hepatitis B Virus (HBV) Vaccine

    The immune response to HBV vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  23. Percentage of Infants With Positive Humoral Response to HBV Vaccine

    Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for HBV vaccine are as follows: Anti-HBs: ≥ 10 mIU/mL.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  24. Mean Titers of Pneumococcal Capsular Polysaccharide, Serotypes, IgG Antibody in Response to 13-valent Pneumococcal Conjugate Vaccine (PCV-13)

    The immune response to PCV-13 vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

  25. Percentage of Infants With Positive Humoral Response to PCV-13

    Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for PCV-13 vaccine are as follows: 13 Valent anti-pneumococcal antibody panel: ≥ 0.35 µg/ml.

    Time frame: Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)

07

Results

Posted Apr 16, 2025

Participant flow

A total of 13 mother-infant pairs took part in the study across 7 sites in the United States, Spain, and the United Kingdom from 16 September 2021 to 13 January 2025.

Treatment and Sampling Period (60 Days)
Participant flow — Treatment and Sampling Period (60 Days)
MilestoneMothersInfants
Started1313
Completed1212
Not completed11
Withdrew: Withdrawal by subject11
Vaccination Period (11 Months)
Participant flow — Vaccination Period (11 Months)
MilestoneMothersInfants
Started1212
Completed1111
Not completed11
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryPercentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First Ocrelizumab Postpartum Infusion

Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose). The percentage of infants with B cell levels below LLN are reported with the two-sided Clopper Pearson 95% confidence interval (CI). B-cell reference ranges by week of life (absolute and percentage counts) are defined by Borriello et al. 2022.

Time frame:
At Day 30
Reported as:
Number · percentage of participants
Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First Ocrelizumab Postpartum Infusion
percentage of participantsInfants
Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN) Measured at Day 30 After the Mother's First Ocrelizumab Postpartum Infusion0 (0 to 30.85)
PrimaryEstimated Average Oral Daily Infant Dosage (ADID)

ADID was calculated as the arithmetic mean of the mother's daily ocrelizumab milk concentration (micrograms/milliliters \[µg/mL\]) over 60 days post-ocrelizumab infusion 1 multiplied by an estimated infant milk intake of 150 milliliters/kilograms/day (mL/kg/day) and based on the weight \[kilograms (kg)\] recorded at the Day 30 visit. Ocrelizumab concentrations reported as below the lower limit of quantification \[LLQ=160 nanograms/millilitres (ng/mL)\] are imputed to zero for the calculation ADID.

Time frame:
Up to Day 60
Reported as:
Mean · micrograms (µg)
Estimated Average Oral Daily Infant Dosage (ADID)
micrograms (µg)Mothers
Estimated Average Oral Daily Infant Dosage (ADID)64.50 (21.415 to 107.587)
SecondaryAbsolute CD19+ B Cell Count in the Infant

Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose).

Time frame:
At Day 30
Reported as:
Median · cells per microliter (cells/µL)
Absolute CD19+ B Cell Count in the Infant
cells per microliter (cells/µL)Infants
Absolute CD19+ B Cell Count in the Infant1431.50 (869.0 to 2241.0)
SecondaryPercentage of CD19+ B Cell in the Infant

Infant blood samples were collected at Day 30 after the mothers received their first postpartum ocrelizumab infusion (regardless of whether women receive a 600 mg or a 2x300 mg dose).

Time frame:
At Day 30
Reported as:
Median · percentage of cells
Percentage of CD19+ B Cell in the Infant
percentage of cellsInfants
Percentage of CD19+ B Cell in the Infant21.80 (10.0 to 31.7)
SecondaryArea Under the Milk Concentration-Time Curve (AUC) of Ocrelizumab in Mature Breastmilk
Time frame:
One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1
Reported as:
Mean · micrograms/millilitres*day (μg/mL*day)
Area Under the Milk Concentration-Time Curve (AUC) of Ocrelizumab in Mature Breastmilk
micrograms/millilitres*day (μg/mL*day)Mothers
Area Under the Milk Concentration-Time Curve (AUC) of Ocrelizumab in Mature Breastmilk3.98 ± 4.93
SecondaryAverage Concentration of Ocrelizumab in Breastmilk (Cmean)
Time frame:
One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1
Reported as:
Mean · μg/mL
Average Concentration of Ocrelizumab in Breastmilk (Cmean)
μg/mLMothers
Average Concentration of Ocrelizumab in Breastmilk (Cmean)0.074 ± 0.077
SecondaryMaximum Concentration (Cmax) of Ocrelizumab in Breastmilk
Time frame:
One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1
Reported as:
Mean · μg/mL
Maximum Concentration (Cmax) of Ocrelizumab in Breastmilk
μg/mLMothers
Maximum Concentration (Cmax) of Ocrelizumab in Breastmilk0.18 ± 0.15
SecondaryTime of Maximum Concentration (Tmax) of Ocrelizumab in Breastmilk
Time frame:
One 600 mg infusion: before infusion and at 24 hours (Day 1), Days 7, 30 and 60 post-infusion; Two 300 mg infusions: before infusion 1 and at 24 hours (Day 1), Days 7, 14, 15 (24 hours after infusion 2), 21, 30 and 60 post-infusion 1
Reported as:
Median · days
Time of Maximum Concentration (Tmax) of Ocrelizumab in Breastmilk
daysMothers
Time of Maximum Concentration (Tmax) of Ocrelizumab in Breastmilk3.97 (0.00 to 59.9)
SecondaryEstimated Maximum Oral Daily Infant Dosage (MDID)

MDID was calculated at the subject level as the peak ocrelizumab milk concentration (μg/mL) multiplied by an estimated infant milk intake of 150 mL/kg/day measured over 60 days after the mother's first postpartum ocrelizumab infusion.

Time frame:
Up to Day 60
Reported as:
Mean · µg
Estimated Maximum Oral Daily Infant Dosage (MDID)
µgMothers
Estimated Maximum Oral Daily Infant Dosage (MDID)153.20 ± 137.15
SecondaryAverage Relative Infant Dose (RID)

Average RID over 60 days was calculated as the ADID (mg/kg/day) divided by the maternal dosage (mg/kg/day) over 60 days multiplied by 100.

Time frame:
Up to Day 60
Reported as:
Mean · percentage
Average Relative Infant Dose (RID)
percentageMothers
Average Relative Infant Dose (RID)0.50 ± 0.58
SecondarySerum Concentration of Ocrelizumab in the Infant at Day 30

Serum concentration of ocrelizumab in the infant measured at Day 30 after the mother's first ocrelizumab postpartum infusion. Concentrations reported as below the lower limit of quantification (LLQ=156 ng/mL) are set to zero for calculation of summary statistics.

Time frame:
At Day 30
Reported as:
Mean · µg/mL
Serum Concentration of Ocrelizumab in the Infant at Day 30
µg/mLInfants
Serum Concentration of Ocrelizumab in the Infant at Day 30NA ± NA
SecondaryPercentage of Mothers With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

Time frame:
Up to approximately 73.3 weeks after first ocrelizumab dose
Reported as:
Number · percentage of participants
Percentage of Mothers With Adverse Events (AEs)
percentage of participantsMothers
Percentage of Mothers With Adverse Events (AEs)76.9
SecondaryPercentage of Infants With AEs

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

Time frame:
Up to approximately 73.3 weeks after first ocrelizumab dose administered to mother
Reported as:
Number · percentage of infants
Percentage of Infants With AEs
percentage of infantsInfants
Percentage of Infants With AEs92.3
SecondaryMean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to Measles, Mumps, and Rubella (MMR) Vaccination

The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. mIU/mL=milli-international units per milliliter.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · mIU/mL
Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to Measles, Mumps, and Rubella (MMR) Vaccination
mIU/mLInfants
Mean Titers of Measles, Immunoglobin G (IgG) Antibody in Response to Measles, Mumps, and Rubella (MMR) Vaccination2590.91 ± 2210.74
SecondaryMean Titers of Mumps, IgG Antibody in Response to MMR Vaccination

The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. RU/mL=relative units per milliliter.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · RU/mL
Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination
RU/mLInfants
Mean Titers of Mumps, IgG Antibody in Response to MMR Vaccination54.19 ± 34.72
SecondaryMean Titers of Rubella, IgG Antibody in Response to MMR Vaccination

The immune response to MMR vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines. IU/mL=international units per milliliter.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · IU/mL
Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination
IU/mLInfants
Mean Titers of Rubella, IgG Antibody in Response to MMR Vaccination94.21 ± 51.39
SecondaryPercentage of Infants With Positive Humoral Response to MMR Vaccination

Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for MMR vaccine are as follows: Anti-Measles Vir IgG(-70)CL: ≥ 120 mIU/mL; Anti-MumpsAT Vir iGG(-70)CL: ≥ 17 RU/mL; Anti-Rub Vir IgG(-70)RUOCL: ≥ 10 IU/mL.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to MMR Vaccination
percentage of infantsInfants
Measles, IgG100
Mumps, IgG77.8
Rubella, IgG100
SecondaryMean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccine

The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · IU/mL
Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccine
IU/mLInfants
Mean Titers of Corynebacterium Diphtheriae, IgG Antibody in Response to Diphtheria-Tetanus-Pertussis (DTP) Vaccine1.94 ± 3.13
SecondaryMean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccine

The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative * COI 0.95-1.04: Equivocal * COI \> 1.04: Positive The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · COI
Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccine
COIInfants
Mean Titers of Bordetella Pertussis, IgG Antibody in Response to DTP Vaccine1.12 ± 0.82
SecondaryMean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccine

The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · IU/mL
Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccine
IU/mLInfants
Mean Titers of Tetanus Toxoid, IgG Antibody in Response to DTP Vaccine1.23 ± 0.43
SecondaryPercentage of Infants With Positive Humoral Response to DTP Vaccine

The immune response to DTP vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. Cut-off Index (COI) = unitless ratio calculated as the signal intensity of the sample divided by the signal of the assay's cut-off calibrator. It is interpreted as follows: * COI \< 0.95: Negative * COI 0.95-1.04: Equivocal * COI \> 1.04: Positive The assay used has not been standardized against WHO International Units (IU/mL) for Bordetella pertussis IgG and therefore, cannot be converted to IU/mL. Higher COI values = a stronger antibody signal, but are not directly correlated with clinical protection. Positivity was defined using the manufacturer's COI cut-off (\>1.04).

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to DTP Vaccine
percentage of infantsInfants
Corynebacterium Diphtheriae, IgG100
Bordetella Pertussis, IgG50
Tetanus Toxoid, IgG100
SecondaryMean Titers of Haemophilus Influenzae Type B (Hib), IgG Antibody in Response to Hib Vaccine

The immune response to Hib vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · micrograms per milliliter (ug/mL)
Mean Titers of Haemophilus Influenzae Type B (Hib), IgG Antibody in Response to Hib Vaccine
micrograms per milliliter (ug/mL)Infants
Mean Titers of Haemophilus Influenzae Type B (Hib), IgG Antibody in Response to Hib Vaccine3.45 ± 4.21
SecondaryPercentage of Infants With Positive Humoral Response to Hib Vaccine

Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for Hib vaccine are as follows: Hib, IgG: ≥ 0.15 µg/mL.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to Hib Vaccine
percentage of infantsInfants
Percentage of Infants With Positive Humoral Response to Hib Vaccine88.9
SecondaryMean Titers of Anti-Hepatitis B Surface Antibody in Response to Hepatitis B Virus (HBV) Vaccine

The immune response to HBV vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · mIU/mL
Mean Titers of Anti-Hepatitis B Surface Antibody in Response to Hepatitis B Virus (HBV) Vaccine
mIU/mLInfants
Mean Titers of Anti-Hepatitis B Surface Antibody in Response to Hepatitis B Virus (HBV) Vaccine1158.01 ± 1263.32
SecondaryPercentage of Infants With Positive Humoral Response to HBV Vaccine

Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for the IgG antibody titer. Seroprotective titer based on vaccine tests for HBV vaccine are as follows: Anti-HBs: ≥ 10 mIU/mL.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to HBV Vaccine
percentage of infantsInfants
Percentage of Infants With Positive Humoral Response to HBV Vaccine100
SecondaryMean Titers of Pneumococcal Capsular Polysaccharide, Serotypes, IgG Antibody in Response to 13-valent Pneumococcal Conjugate Vaccine (PCV-13)

The immune response to PCV-13 vaccine was assessed 1 month after the first dose of MMR vaccine (if the first dose is administered at 11 months of age or later) or 1 month after the second dose of MMR vaccine (if the first dose is administered before 11 months of age), or at Month 13 of chronological age if MMR vaccine was not planned to be administered. This was to evaluate whether infants can mount humoral immune responses to clinically relevant vaccines.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Mean · ug/mL
Mean Titers of Pneumococcal Capsular Polysaccharide, Serotypes, IgG Antibody in Response to 13-valent Pneumococcal Conjugate Vaccine (PCV-13)
ug/mLInfants
Pneumococcal Capsular Polysaccharide, Serotype 1, IgG4.80 ± 6.38
Pneumococcal Capsular Polysaccharide, Serotype 3, IgG2.56 ± 3.16
Pneumococcal Capsular Polysaccharide, Serotype 4, IgG8.28 ± 9.18
Pneumococcal Capsular Polysaccharide, Serotype 5, IgG9.98 ± 15.72
Pneumococcal Capsular Polysaccharide, Serotype 6A, IgG27.28 ± 34.50
Pneumococcal Capsular Polysaccharide, Serotype 6B, IgG27.02 ± 70.85
Pneumococcal Capsular Polysaccharide, Serotype 7F, IgG9.44 ± 14.11
Pneumococcal Capsular Polysaccharide, Serotype 9V, IgG4.21 ± 3.66
Pneumococcal Capsular Polysaccharide, Serotype 14, IgG14.93 ± 14.49
Pneumococcal Capsular Polysaccharide, Serotype 18C, IgG9.62 ± 11.47
Pneumococcal Capsular Polysaccharide, Serotype 19A, IgG1.70 ± 1.41
Pneumococcal Capsular Polysaccharide, Serotype 19F, IgG45.83 ± 80.11
Pneumococcal Capsular Polysaccharide, Serotype 23F, IgG10.50 ± 13.17
SecondaryPercentage of Infants With Positive Humoral Response to PCV-13

Percentage of infants with positive humoral response (seroprotective titers as defined for the individual vaccine) was presented for each IgG antibody titer. Seroprotective titer based on vaccine tests for PCV-13 vaccine are as follows: 13 Valent anti-pneumococcal antibody panel: ≥ 0.35 µg/ml.

Time frame:
Up to 1 month after the first or second dose of MMR vaccine (at approximately Month 13)
Reported as:
Number · percentage of infants
Percentage of Infants With Positive Humoral Response to PCV-13
percentage of infantsInfants
Pneumococcal Capsular Polysaccharide, Serotype 1, IgG80
Pneumococcal Capsular Polysaccharide, Serotype 3, IgG70
Pneumococcal Capsular Polysaccharide, Serotype 4, IgG80
Pneumococcal Capsular Polysaccharide, Serotype 5, IgG90
Pneumococcal Capsular Polysaccharide, Serotype 6A, IgG100
Pneumococcal Capsular Polysaccharide, Serotype 6B, IgG80
Pneumococcal Capsular Polysaccharide, Serotype 7F, IgG100
Pneumococcal Capsular Polysaccharide, Serotype 9V, IgG90
Pneumococcal Capsular Polysaccharide, Serotype 14, IgG100
Pneumococcal Capsular Polysaccharide, Serotype 18C, IgG80
Pneumococcal Capsular Polysaccharide, Serotype 19A, IgG60
Pneumococcal Capsular Polysaccharide, Serotype 19F, IgG100
Pneumococcal Capsular Polysaccharide, Serotype 23F, IgG80

Adverse events

Collected over Mothers and Infants: Up to approximately 73.3 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mothers0/13 (0%)0/13 (0%)10/13 (76.9%)
Infants0/13 (0%)0/13 (0%)12/13 (92.3%)
Most frequent other events
Showing 10 of 52
Most frequent other events
EventMothersInfants
COVID-19Infections and infestations6/134/13
PyrexiaGeneral disorders1/133/13
Ear infectionInfections and infestations0/133/13
NasopharyngitisInfections and infestations3/133/13
Infusion related reactionInjury, poisoning and procedural complications3/130/13
PainGeneral disorders2/131/13
BronchiolitisInfections and infestations0/132/13
Hand-foot-and-mouth diseaseInfections and infestations0/132/13
MastitisInfections and infestations2/130/13
Upper respiratory tract infectionInfections and infestations2/132/13

Baseline characteristics

Safety Analysis Set Mothers (SAFM) included all mothers who met the eligibility criteria and received any post-partum dose of ocrelizumab. Safety Analysis Set Infants (SAFI) included all the infants of women in the Full Analysis Set Mothers (FASM) population. As consent for race and ethnicity was not obtained, this data has not been reported.

Age, Customized
Age, Customized(Participants)MothersInfantsTotal
Preterm newborn infants (gestational age <37 weeks)000
Newborns (0-27 days)088
Infants and toddlers (28 days-23 months)055
Children (2-11 years)000
Adolescents (12-17 years)000
Adults (18-64 years)13013
From 65-84 years000
85 years and over000
Sex: Female, Male
Sex: Female, Male(Participants)MothersInfantsTotal
Female13619
Male077
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MothersInfantsTotal
Not reported131326
08

Study locations

8 sites
  • University of California San Francisco
    San Francisco, California 94158, United States
  • University Of Colorado
    Aurora, Colorado 80045, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611-2987, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
  • Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis
    Owosso, Michigan 48867, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Hosp. Clinico San Carlos
    Madrid, 28040, Spain
  • Queen Mary University of London
    London, EC1M 6BQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Mar 2024, 30 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 30 months is close to that.

Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2021
First posted
Aug 10, 2021
StartActual
Sep 16, 2021
Primary completionActual
Mar 29, 2024
CompletionActual
Jan 13, 2025
Results first posted
Apr 16, 2025
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04998851
Lead sponsor
Hoffmann-La Roche
Collaborators
PPD Development, LP, Laboratory Corporation of America, Illingworth Research Group
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
Sep 16, 2021
Primary completion
Mar 29, 2024
Completion
Jan 13, 2025
Results posted
Apr 16, 2025
Last update
Jan 14, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion